Abstract: The present invention relates to the field of pharmaceutical compositions suitable for the oral administration of an active in animals. In particular, the present invention relates to a liquid drug-containing formulation and to the use thereof. The present invention further relates to the use of a liquid formulation aid composition comprising at least one natural oil of herbal origin in a liquid drug-containing formulation for improving the acceptance or voluntary acceptance of drug intake in animal.

Abstract: The invention relates to a formed body for the administration to animals and to a process for the production of the formed body for the administration to animals. The formed body serves in particular for the oral administration of pharmaceutically active substances to animals. The formed body for the administration to animals comprises one or more pharmaceutically active substance, one or more flavouring agents, one or more binding agents, one or more gel-forming agents, one or more fillers, water and glycerol.

Abstract: The present invention relates to a composition comprising tigolaner and, optionally endoparasiticidal agents, a method for its manufacture and its use as a medicament for controlling parasites. Compositions can include tigolaner and 1,2-isopropylideneglycerol, or the composition can include praziquantel, emodepside a solvent component, and tigolaner. The composition can be used in the treatment and/or prevention of parasite infections in animals.

Abstract: The present invention refers to a pharmaceutical preparation (10) comprising a first pharmaceutical composition having a matrix material and pharmaceutically active ingredients distributed within the matrix material, wherein the first pharmaceutical composition comprises Praziquantel, Pyrantel and Febantel as pharmaceutical active ingredients, wherein the preparation (10) comprises a second pharmaceutical composition having a matrix material and at least one of avermectins and milbemycins such as Moxidectin as pharmaceutically active ingredient distributed within the matrix material, wherein the preparation (10) is provided in a multi-layer structure such, that the first composition is provided in a first layer (12) and the second composition is provided in a second layer (14), wherein the first layer (12) and the second layer (14) are separated by a barrier layer (16) being provided between the first layer (12) and the second layer (14).

Abstract: The present invention relates to tablets for animals, having improved acceptance and good storage stability.

Abstract: The present invention relates to tablets for animals, having improved acceptance and good storage stability.

Abstract: A solid pharmaceutical preparation The present invention refers to a pharmaceutical preparation (10) comprising a first pharmaceutical composition having a matrix material and pharmaceutically active ingredients distributed within the matrix material, wherein the first pharmaceutical composition comprises Praziquantel, Pyrantel and Febantel as pharmaceutical active ingredients, wherein the preparation (10) comprises a second pharmaceutical composition having a matrix material and at least one of avermectins and milbemycins such as Moxidectin as pharmaceutically active ingredient distributed within the matrix material, wherein the preparation (10) is provided in a multi-layer structure such, that the first composition is provided in a first layer (12) and the second composition is provided in a second layer (14), wherein the first layer (12) and the second layer (14) are separated by a barrier layer (16) being provided between the first layer (12) and the second layer (14).

Abstract: The present invention relates to tablets for animals, having improved acceptance and good storage stability.

Abstract: The present invention relates to a process for preparing shaped articles for administration to animals, to the shaped articles obtainable according to the process and to their use.

Abstract: The invention relates to preparations comprising amorphous emodepside in a polyvinylpyrrolidone matrix, pharmaceuticals comprising such preparations, and their use against endoparasites in animals or humans.

Abstract: The invention relates to preparations comprising amorphous emodepside in a polyvinylpyrrolidone matrix, pharmaceuticals comprising such preparations, and their use against endoparasites in animals or humans.

Abstract: The present invention generally relates to soft chewables, especially suitable for delivering active ingredients to animals and processes for the preparation thereof. In various embodiments, the soft chewable comprises a pharmaceutically effective amount of at least one active ingredient, a flavoring agent, a disintegrant, a humectant, an antioxidant, a preservative, and water. In accordance with preferred embodiments, the soft chewable is essentially free of starch, oil, glycols, waxes, and soy products.

Abstract: The invention relates to preparations comprising amorphous emodepside in a polyvinylpyrrolidone matrix, pharmaceuticals comprising such preparations, and their use against endoparasites in animals or humans.

Abstract: The present invention relates to tablets for animals, having improved acceptance and good storage stability.

Abstract: The invention relates to a solid pharmaceutical preparation with delayed release of the active ingredients which is suitable in particular for use in animals.

Abstract: The present invention generally relates to soft chewables, especially suitable for delivering active ingredients to animals and processes for the preparation thereof. In various embodiments, the soft chewable comprises a pharmaceutically effective amount of at least one active ingredient, a flavoring agent, a disintegrant a humectant, an antioxidant, a preservative, and water. In accordance with preferred embodiments, the soft chewable is essentially free of starch, oil glycols, waxes, and soy products.

Abstract: The present invention relates to an oil-based preparation comprising a triazine which is active against parasitic protozoans and an anthelmintic cyclodepsipeptide, which preparation is particularly suitable for the oral application of the active substance combination in animals.

Abstract: The present invention relates to an orally administrable preparation comprising a quinolone antibiotic which releases the active compound with a delay.

Abstract: The invention relates to extrudates containing at least one pharmaceutically active substance in the form of needles, wherein the ratio of the particle size of the needle-shaped pharmaceutically active substance to the strand diameter is at least 1:15, and the use of these extrudates for the production of medicaments.

Abstract: The present invention relates to the combination of aminophenylamidine derivatives with cyclic depsipeptides, to products comprising this combination, and to the use of these active substances in combination for controlling endoparasites in humans and in animals.